– Treatment group participants experienced a reduction in key inflammatory biomarker
– Observed a reduction in time of hospitalization and death rate with no deaths recorded in treatment group
New York, NY, and Tel Aviv, ISRAEL, Sept. 30, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Todos Medical, Ltd. (“Todos Medical”) (OTCQB: TOMDF) , a comprehensive medical diagnostics and related solutions company, today announced results from an observational study of 32 hospitalized COVID-19 patients treated with Tollovir®, the Company’s proprietary oral antiviral 3CL protease inhibitor treatment. This exploratory study of 11 treated patients was compared with 21 randomly selected untreated patients in the hospitalized setting …
Read the source article at Stock Market Quotes and News
2021-09-30 14:09:01
